13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001746382
Total reported value
$47.5M
$47.5M
23 檔
56.1%
According to the latest 13F quarterly dataset, Altium Capital Management LLC managed an equity portfolio of $47.5M at the end of Q1 2025, spanning 23 distinct U.S. exchange-listed positions.
In Q1 2025, Altium Capital Management LLC displayed an active expansion posture, initiating 23 new positions and adding to 0 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ZVRA | Zevra Therapeutics Inc | Stock-Other | 23.23% | — | -30.41% | |
| 2 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 16.27% | — | — | |
| 3 | EOLS | Evolus Inc | Stock-Other | 8.59% | — | -56.76% | |
| 4 | XTNT | Xtant Medical Holdings Inc | Stock-Other | 8.21% | — | -2.19% | |
| 5 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 7.91% | — | -7.37% | |
| 6 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 5.63% | — | -76.58% | |
| 7 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 5.11% | — | -9.02% | |
| 8 | PROF | Profound Medical CORP | Stock-Other | 5.06% | — | -25.65% | |
| 9 | EPIEUR | Essa Pharma Inc | Stock-Other | 4.00% | — | -26.44% | |
| 10 | SKYE | Skye Bioscience Inc | Stock-Other | 3.47% | — | -20.56% | |
| 11 | ACOG | Alpha Cognition Inc | Stock-Other | 2.16% | — | -35.49% | |
| 12 | RZLT | Rezolute Inc | Stock-Other | 2.12% | — | -82.06% | |
| 13 | NKTREUR | Nektar Therapeutics | Stock-Other | 1.72% | — | -64.95% | |
| 14 | AVR | Anteris Technologies Global | Stock-Other | 1.48% | — | -77.13% | |
| 15 | LRMR | Larimar Therapeutics Inc | Stock-Other | 1.42% | — | -69.68% | |
| 16 | PMNEUR | Promis Neurosciences Inc | Stock-Other | 0.96% | — | -1.23% | |
| 17 | ✓ | Envveno Medical CORP | Stock-Other | 0.78% | — | -60.24% | |
| 18 | GBS1EUR | Gbs Inc | Stock-Other | 0.52% | — | — | |
| 19 | KPTI | Karyopharm Therapeutics Inc | Stock-Other | 0.44% | — | — | |
| 20 | ✓ | Sharps Technology Inc | Stock-Other | 0.27% | — | — | |
| 21 | ✓ | Stock-Other | 0.26% | — | — | ||
| 22 | ✓ | Stock-Other | 0.23% | — | — | ||
| 23 | SRXH | Srx Health Solutions Inc | Stock-Other | 0.16% | — | -67.09% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ZVRA | Zevra Therapeutics Inc | — | NEW | New buy |
| 2 | ALNY | Alnylam Pharmaceuticals Inc | — | NEW | New buy |
| 3 | EOLS | Evolus Inc | — | NEW | New buy |
| 4 | XTNT | Xtant Medical Holdings Inc | — | NEW | New buy |
| 5 | ✓ | Avadel Pharmaceuticals PLC ADR | — | NEW | New buy |
| 6 | XENE | Xenon Pharmaceuticals Inc | — | NEW | New buy |
| 7 | CTNM | Contineum Therapeutics Inc-a | — | NEW | New buy |
| 8 | PROF | Profound Medical CORP | — | NEW | New buy |
| 9 | EPIEUR | Essa Pharma Inc | — | NEW | New buy |
| 10 | SKYE | Skye Bioscience Inc | — | NEW | New buy |
| 11 | ACOG | Alpha Cognition Inc | — | NEW | New buy |
| 12 | RZLT | Rezolute Inc | — | NEW | New buy |
| 13 | NKTREUR | Nektar Therapeutics | — | NEW | New buy |
| 14 | AVR | Anteris Technologies Global | — | NEW | New buy |
| 15 | LRMR | Larimar Therapeutics Inc | — | NEW | New buy |
| 16 | PMNEUR | Promis Neurosciences Inc | — | NEW | New buy |
| 17 | ✓ | Envveno Medical CORP | — | NEW | New buy |
| 18 | GBS1EUR | Gbs Inc | — | NEW | New buy |
| 19 | KPTI | Karyopharm Therapeutics Inc | — | NEW | New buy |
| 20 | ✓ | Sharps Technology Inc | — | NEW | New buy |
| 21 | ✓ | — | NEW | New buy | |
| 22 | ✓ | — | NEW | New buy | |
| 23 | SRXH | Srx Health Solutions Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Altium Capital Management LLC reported a total U.S. public equity portfolio value of $47.5M across 23 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ZVRA, ALNY, EOLS) accounted for 56.1% of total reported equity market value during Q1 2025.
Top New Position Initiated
ZVRA
市值: $9.6M
During Q1 2025, Altium Capital Management LLC's top holdings by market value included ZVRA (23.2%)、ALNY (16.3%)、EOLS (8.6%). The largest single position, ZVRA, represented 23.2% of total portfolio value.
In Q1 2025, Altium Capital Management LLC made 23 total portfolio adjustments, initiating 23 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.